Parallel Advisors, LLC Dbv Technologies S.A. Transaction History

Parallel Advisors, LLC

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 01, 2022	BUY	$1.15 - $3.25 $434 - $1,228	378 New	378 $1,000
Q1 2022 Apr 28, 2022	SELL	$1.22 - $1.77 $522 - $757	-428 Closed	0 $0
Q4 2021 Jan 20, 2022	BUY	$1.39 - $5.58 $594 - $2,388	428 New	428 $1,000
Q4 2020 Feb 02, 2021	SELL	$1.38 - $3.01 $1,219 - $2,660	-884 Closed	0 $0
Q2 2020 Jul 16, 2020	SELL	$3.74 - $6.28 $598 - $1,004	-160 Reduced 15.33%	884 $3,000
Q1 2020 Apr 27, 2020	BUY	$2.33 - $12.98 $2,432 - $13,551	1,044 New	1,044 $4,000
Q4 2019 Jan 30, 2020	SELL	$6.75 - $11.15 $1,336 - $2,207	-198 Closed	0 $0
Q2 2019 Aug 05, 2019	BUY	$7.58 - $10.0 $1,500 - $1,980	198 New	198 $2,000
Q4 2018 Feb 05, 2019	SELL	$5.75 - $21.85 $2,242 - $8,521	-390 Closed	0 $0
Q3 2018 Nov 01, 2018	BUY	$16.81 - $24.58 $4,605 - $6,734	274 Added 236.21%	390 $9,000
Q2 2018 Jul 30, 2018	SELL	$18.6 - $24.94 $3,868 - $5,187	-208 Reduced 64.2%	116 $2,000
Q1 2018 May 08, 2018	SELL	$20.86 - $26.6 $709 - $904	-34 Reduced 9.5%	324 $7,000
Q4 2017 Feb 13, 2018	BUY	$20.9 - $49.36 $6,479 - $15,301	310 Added 645.83%	358 $9,000
Q3 2017 Nov 15, 2017	BUY	$39.62 - $46.17 $1,901 - $2,216	48	48 $1,000

3.2K

Ticker DBVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,776,992
Market Cap $599M
Description
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents...

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Parallel Advisors, LLC with notifications on news.